Literature DB >> 21195304

Genetic modification of T cells.

Chiara Bonini1, Malcolm K Brenner, Helen E Heslop, Richard A Morgan.   

Abstract

Adoptively transferred T cells have shown activity in treating viral infections after hemopoietic transplantation and anti-tumor activity against some malignancies such as melanoma and lymphoma. Current research focuses on defining the optimum type of cell for transfer to improve persistence and genetically modifying infused T cells to augment function, overcome tumor evasion strategies and allow ablation should adverse effects occur. Copyright Â
© 2011 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21195304      PMCID： PMC3053011          DOI： 10.1016/j.bbmt.2010.09.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  47 in total

1.  Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Authors:  Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas C Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-24       Impact factor: 11.205

2.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

3.  A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Authors:  Yangbing Zhao; Qiong J Wang; Shicheng Yang; James N Kochenderfer; Zhili Zheng; Xiaosong Zhong; Michel Sadelain; Zelig Eshhar; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

Review 4.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

5.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Authors:  Fabio Ciceri; Chiara Bonini; Maria Teresa Lupo Stanghellini; Attilio Bondanza; Catia Traversari; Monica Salomoni; Lucia Turchetto; Scialini Colombi; Massimo Bernardi; Jacopo Peccatori; Alessandra Pescarollo; Paolo Servida; Zulma Magnani; Serena K Perna; Veronica Valtolina; Fulvio Crippa; Luciano Callegaro; Elena Spoldi; Roberto Crocchiolo; Katharina Fleischhauer; Maurilio Ponzoni; Luca Vago; Silvano Rossini; Armando Santoro; Elisabetta Todisco; Jane Apperley; Eduardo Olavarria; Shimon Slavin; Eva M Weissinger; Arnold Ganser; Michael Stadler; Evangelia Yannaki; Athanasios Fassas; Achilles Anagnostopoulos; Marco Bregni; Corrado Gallo Stampino; Paolo Bruzzi; Claudio Bordignon
Journal:  Lancet Oncol       Date:  2009-04-01       Impact factor: 41.316

6.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Eric Y Chen; Brent L Wood; Harvey A Greisman; Xiaojun Qian; Scott E James; Andrew Raubitschek; Stephen J Forman; Ajay K Gopal; John M Pagel; Catherine G Lindgren; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

Review 7.  How tumours escape mass destruction.

Authors:  T J Stewart; S I Abrams
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

8.  IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.

Authors:  Shin Kaneko; Sara Mastaglio; Attilio Bondanza; Maurilio Ponzoni; Francesca Sanvito; Luca Aldrighetti; Marina Radrizzani; Simona La Seta-Catamancio; Elena Provasi; Anna Mondino; Toshiro Nagasawa; Katharina Fleischhauer; Vincenzo Russo; Catia Traversari; Fabio Ciceri; Claudio Bordignon; Chiara Bonini
Journal:  Blood       Date:  2008-10-31       Impact factor: 22.113

Review 9.  Graft-versus-leukemia effects of transplantation and donor lymphocytes.

Authors:  Hans-Jochem Kolb
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

10.  Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Authors:  Juan F Vera; Valentina Hoyos; Barbara Savoldo; Concetta Quintarelli; Greta M P Giordano Attianese; Ann M Leen; Hao Liu; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454
View more
  19 in total

Review 1.  Adoptive T-Cell Immunotherapy.

Authors:  Stephen Gottschalk; Cliona M Rooney
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  CAR T cells for acute myeloid leukemia: the LeY of the land.

Authors:  Malcolm K Brenner
Journal:  Mol Ther       Date:  2013-11       Impact factor: 11.454

3.  Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation.

Authors:  Naoki Kunii; Yangbing Zhao; Shuguang Jiang; Xiaojun Liu; John Scholler; Lakshmi Balagopalan; Lawrence E Samelson; Michael C Milone; Carl H June
Journal:  Hum Gene Ther       Date:  2012-11-06       Impact factor: 5.695

4.  Conditional negative selection of gene-modified hematopoietic stem cells.

Authors:  Christopher Baum
Journal:  Mol Ther       Date:  2012-10       Impact factor: 11.454

Review 5.  Genetically modified T-cell therapy for osteosarcoma.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

6.  Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.

Authors:  Steven A Rosenberg; James N Kochenderfer
Journal:  Mol Ther       Date:  2011-11       Impact factor: 11.454

7.  Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64.

Authors:  Parijat Bhatnagar; Zheng Li; Yoonsu Choi; Jianfeng Guo; Feng Li; Daniel Y Lee; Matthew Figliola; Helen Huls; Dean A Lee; Tomasz Zal; King C Li; Laurence J N Cooper
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 8.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

Review 9.  Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors:  Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal:  Neurosurg Clin N Am       Date:  2012-07       Impact factor: 2.509

Review 10.  Cancer vaccines and T cell therapy.

Authors:  Katayoun Rezvani; Joshua D Brody; Holbrook E Kohrt; Aaron C Logan; Ranjana Advani; Debra Katherine Czerwinski; Wen-Kai Weng; Robert S Negrin; Victoria Carlton; Malek Faham; Ronald Levy; John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-03       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.